The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Dynorphin Is a Specific Endogenous Ligand of the κ Opioid Receptor
Abstract
In the guinea pig ileum myenteric plexus—longitudinal muscle preparation, dynorphin-(1—13) and the prototypical κ agonist ethylketocyclazocine had equally poor sensitivity to naloxone antagonism and showed selective cross protection in receptor inactivation experiments with the alkylating antagonist β-chlornaltrexamine. In binding assays with membranes from guinea pig brain, ethylketocyclazocine and dynorphin-(1—13) amide were more potent in displacing tritium-labeled ethylketocyclazocine than in displacing typical μ and δ opioid receptor ligands. In the two preparations studied, the dynorphin receptor appears to be the same as the κ opioid receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
Endogenous opioid peptides: multiple agonists and receptors
Lord, J. A. H., Waterfield, A. A., Hughes, J., & Kosterlitz, H. W. (1977) · Nature · doi:10.1038/267495a0 · Cited by 2,485
Dynorphin-(1-13), an extraordinarily potent opioid peptide.
Goldstein, A., Tachibana, S., Lowney, L. I., Hunkapiller, M., & Hood, L. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.12.6666 · Cited by 882
Multiple opiate receptors. Enkephalins and morphine bind to receptors of different specificity.
Chang, K. J., & Cuatrecasas, P. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)30115-1 · Cited by 683
Gilbert, P. E., & Martin, W. R. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30572-0 · Cited by 487
Specific receptor for the opioid peptide dynorphin: structure--activity relationships.
Chavkin, C., & Goldstein, A. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.10.6543 · Cited by 423
Self-citationCHARACTERIZATION OF THE k‐SUBTYPE OF THE OPIATE RECEPTOR IN THE GUINEA‐PIG BRAIN
KOSTERLITZ, H. W., PATERSON, S. J., & ROBSON, L. E. (1981) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1981.tb08749.x · Cited by 422
CHANG, K.-J., COOPER, B. R., HAZUM, E., & CUATRECASAS, P. (1979) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)11410-7 · Cited by 408
Goldstein, A., Fischli, W., Lowney, L. I., Hunkapiller, M., & Hood, L. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.11.7219 · Cited by 399
Self-citationImmunoreactive dynorphin in pituitary and brain.
Goldstein, A., & Ghazarossian, V. E. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.10.6207 · Cited by 218
Self-citation
Cited by
Vanderschuren, L. J. M. J., & Kalivas, P. W. (2000) · Psychopharmacology · doi:10.1007/s002130000493 · Cited by 1,346
Endogenous Opioids: Biology and Function
Akil, H., Watson, S. J., Young, E., Lewis, M. E., Khachaturian, H., & Walker, J. M. (1984) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.07.030184.001255 · Cited by 1,224
A Role for Brain Stress Systems in Addiction
Koob, G. F. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.012 · Cited by 1,056
“Dynorphin/k Opioid System Dynorphins are opioid peptides that derive from the prodynorphin precursor and contain the leucine (leu)-enkephalin sequence at the N-terminal portion of the molecule and are the presumed endogenous ligands for the k opioid receptor (Chavkin et al., 1982).”
Mechanisms of Cellular Uptake of Cell-Penetrating Peptides
Madani, F., Lindberg, S., Langel, Ü., Futaki, S., & Gräslund, A. (2011) · Journal of Biophysics · doi:10.1155/2011/414729 · Cited by 984
Han, J.-S. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2003.12.019 · Cited by 816
Neuropeptide Transmission in Brain Circuits
van den Pol, A. N. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.014 · Cited by 810
“Dynorphin is an opioid neuropeptide which acts at kappa Gi/Go-coupled opioid receptors, leading to cellular inhibition (Chavkin et al., 1982) by presynaptic inhibition, activation of K currents, or attenuation of voltage-gated calcium channels.”
BackgroundSalvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist
Roth, B. L., Baner, K., Westkaemper, R., Siebert, D., Rice, K. C., Steinberg, S., Ernsberger, P., & Rothman, R. B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182234399 · Cited by 784
Navarro, V. M., Gottsch, M. L., Chavkin, C., Okamura, H., Clifton, D. K., & Steiner, R. A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1569-09.2009 · Cited by 779
Self-citationRegulation of cocaine reward by CREB
Carlezon, W. A., Thome, J., Olson, V. G., Lane-Ladd, S. B., Brodkin, E. S., Hiroi, N., Duman, R. S., Neve, R. L., & Nestler, E. J. (1998) · Science · doi:10.1126/science.282.5397.2272 · Cited by 767
Waldhoer, M., Bartlett, S. E., & Whistler, J. L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073940 · Cited by 740
The Dysphoric Component of Stress Is Encoded by Activation of the Dynorphin κ-Opioid System
Land, B. B., Bruchas, M. R., Lemos, J. C., Xu, M., Melief, E. J., & Chavkin, C. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4458-07.2008 · Cited by 601
Self-citationThe dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors
Bruchas, M. R., Land, B. B., & Chavkin, C. (2010) · Brain Research · doi:10.1016/j.brainres.2009.08.062 · Cited by 544
“potent endogenous opioid peptide dynorphin (Chavkin et al., 1982), and each of the dynorphin opioids has structural features conferring KOR selectivity (Chavkin and Goldstein, 1981).”
BackgroundSelf-citationSpanagel, R., Herz, A., & Shippenberg, T. S. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb04963.x · Cited by 539
Distribution of dynorphin and enkephalin peptides in the rat brain
Fallon, J. H., & Leslie, F. M. (1986) · Journal of Comparative Neurology · doi:10.1002/cne.902490302 · Cited by 526
Pliakas, A. M., Carlson, R. R., Neve, R. L., Konradi, C., Nestler, E. J., & Carlezon, W. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07397.2001 · Cited by 509
“Blockade of opioid receptors, on which dynorphin acts (Chavkin et al., 1982), prevents the aversive effects of elevated CREB expression in the NAc (Carlezon et al., 1998).”
BackgroundThe binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties
Magnan, J., Paterson, S. J., Tavani, A., & Kosterlitz, H. W. (1982) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00495865 · Cited by 509
A unified framework for addiction: Vulnerabilities in the decision process
Redish, A. D., Jensen, S., & Johnson, A. (2008) · Behavioral and Brain Sciences · doi:10.1017/s0140525x0800472x · Cited by 501
Addiction as a stress surfeit disorder
Koob, G. F., Buck, C. L., Cohen, A., Edwards, S., Park, P. E., Schlosburg, J. E., Schmeichel, B., Vendruscolo, L. F., Wade, C. L., Whitfield, T. W., et al. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.024 · Cited by 483
“Dynorphins bind to all three opioid receptors but show a preference for κ receptors (Chavkin et al., 1982).”
BackgroundInfluentialInitiation and adaptation: a paradigm for understanding psychotropic drug action
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.2.151 · Cited by 490
Dynorphin, stress, and depression
Knoll, A. T., & Carlezon, W. A. (2010) · Brain Research · doi:10.1016/j.brainres.2009.09.074 · Cited by 465
Sex differences in neural mechanisms mediating reward and addiction
Becker, J. B., & Chartoff, E. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0125-6 · Cited by 459
Morley, J. E., Levine, A. S., Yim, G. K., & Lowy, M. T. (1983) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(83)90020-9 · Cited by 451
Dynorphin1–8 and dynorphin1–9 are ligands for the κ-subtype of opiate receptor
Corbett, A. D., Paterson, S. J., McKnight, A. T., Magnan, J., & Kosterlitz, H. W. (1982) · Nature · doi:10.1038/299079a0 · Cited by 447
Pharmacology of nociceptin and its receptor: a novel therapeutic target
Calo', G., Guerrini, R., Rizzi, A., Salvadori, S., & Regoli, D. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703219 · Cited by 437
McLaughlin, J. P., Marton-Popovici, M., & Chavkin, C. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-13-05674.2003 · Cited by 430
Self-citationMatthews, R. T., & German, D. C. (1984) · Neuroscience · doi:10.1016/0306-4522(84)90048-4 · Cited by 426
The role of the dynorphin–κ opioid system in the reinforcing effects of drugs of abuse
Wee, S., & Koob, G. F. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1825-8 · Cited by 398
Addiction is a Reward Deficit and Stress Surfeit Disorder
Koob, G. F. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00072 · Cited by 397
Dynorphin and the pathophysiology of drug addiction
Shippenberg, T. S., Zapata, A., & Chefer, V. I. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.06.011 · Cited by 387
“DYN is the major posttranslational product of the PDYN gene and the presumed endogenous ligand for the KOPr (Chavkin et al., 1982; Corbett et al. 1982).”
BackgroundStructure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor
Che, T., Majumdar, S., Zaidi, S. A., Ondachi, P., McCorvy, J. D., Wang, S., Mosier, P. D., Uprety, R., Vardy, E., Krumm, B. E., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.011 · Cited by 365
Cole, R. L., Konradi, C., Douglass, J., & Hyman, S. E. (1995) · Neuron · doi:10.1016/0896-6273(95)90225-2 · Cited by 365
Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior
Steiner, H., & Gerfen, C. R. (1998) · Experimental Brain Research · doi:10.1007/s002210050545 · Cited by 365
Isolation and structural organization of the human preproenkephalin B gene
Horikawa, S., Takai, T., Toyosato, M., Takahashi, H., Noda, M., Kakidani, H., Kubo, T., Hirose, T., Inayama, S., Hayashida, H., et al. (1983) · Nature · doi:10.1038/306611a0 · Cited by 352
Molecular biology of the opioid receptors: structures, functions and distributions
Minami, M., & Satoh, M. (1995) · Neuroscience Research · doi:10.1016/0168-0102(95)00933-k · Cited by 346
Distinct subpopulations of nucleus accumbens dynorphin neurons drive aversion and reward
Al-Hasani, R., McCall, J. G., Shin, G., Gomez, A. M., Schmitz, G. P., Bernardi, J. M., Pyo, C.-O., Park, S. I., Marcinkiewcz, C. M., Crowley, N. A., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.08.019 · Cited by 345
“KORs are endogenously activated by the peptide dynorphin (dyn), which is cleaved from the precursor prodynorphin (Chavkin et al., 1982).”
BackgroundWeisskopf, M. G., Zalutsky, R. A., & Nicoll, R. A. (1993) · Nature · doi:10.1038/362423a0 · Cited by 336
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324
Molecular alterations in the neostriatum of human cocaine addicts
Hurd, Y. L., & Herkenham, M. (1993) · Synapse · doi:10.1002/syn.890130408 · Cited by 323
Dynorphin immunocytochemistry in the rat central nervous system
Khachaturian, H., Watson, S. J., Lewis, M. E., Coy, D., Goldstein, A., & Akil, H. (1982) · Peptides · doi:10.1016/0196-9781(82)90063-8 · Cited by 320
Self-citationKinase cascades and ligand-directed signaling at the kappa opioid receptor
Bruchas, M. R., & Chavkin, C. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1806-y · Cited by 317
Self-citationOpioid Receptors and their Ligands
Janecka, A., Fichna, J., & Janecki, T. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043451618 · Cited by 311
30 years of dynorphins — New insights on their functions in neuropsychiatric diseases
Schwarzer, C. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.05.006 · Cited by 289
Enkephalin systems in diencephalon and brainstem of the rat
Khachaturian, H., Lewis, M. E., & Watson, S. J. (1983) · Journal of Comparative Neurology · doi:10.1002/cne.902200305 · Cited by 286
Shook, J. E., Watkins, W. D., & Camporesi, E. M. (1990) · American Review of Respiratory Disease · doi:10.1164/ajrccm/142.4.895 · Cited by 280
Gear, R. W., Miaskowski, C., Gordon, N. C., Paul, S. M., Heller, P. H., & Levine, J. D. (1999) · Pain · doi:10.1016/s0304-3959(99)00119-0 · Cited by 274
κ and δ-opioid receptor agonists differentially inhibit striatal dopamine and acetylcholine release
Mulder, A. H., Wardeh, G., Hogenboom, F., & Frankhuyzen, A. L. (1984) · Nature · doi:10.1038/308278a0 · Cited by 274
Effects of κ-opioid receptor ligands on intracranial self-stimulation in rats
Todtenkopf, M. S., Marcus, J. F., Portoghese, P. S., & Carlezon, W. A. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1680-y · Cited by 273
“These behavioral effects appear related to the ability of CREB to regulate transcription of dynorphin (Cole et al. 1995; Carlezon et al. 1998), an endogenous kopioid receptor ligand (Chavkin et al. 1982).”
BackgroundBiochemistry of the enkephalins and enkephalin-containing peptides
Udenfriend, S., & Kilpatrick, D. L. (1983) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(83)90149-2 · Cited by 271
Mansour, A., Hoversten, M. T., Taylor, L. P., Watson, S. J., & Akil, H. (1995) · Brain Research · doi:10.1016/0006-8993(95)00928-j · Cited by 267
Gross, R. A., & Macdonald, R. L. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.15.5469 · Cited by 264
Bruchas, M. R., Macey, T. A., Lowe, J. D., & Chavkin, C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513640200 · Cited by 258
Self-citationRole of kappa-opioid receptors in stress and anxiety-related behavior
Van’t Veer, A., & Carlezon, W. A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3195-5 · Cited by 257
Molecular pharmacology of the opioid receptors
Satoh, M., & Minami, M. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)02011-x · Cited by 257
Muschamp, J. W., Hollander, J. A., Thompson, J. L., Voren, G., Hassinger, L. C., Onvani, S., Kamenecka, T. M., Borgland, S. L., Kenny, P. J., & Carlezon, W. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315542111 · Cited by 256
Neurobiology of dysregulated motivational systems in drug addiction
Edwards, S., & Koob, G. F. (2010) · Future Neurology · doi:10.2217/fnl.10.14 · Cited by 157
The one-two punch of alcoholism: role of central amygdala dynorphins/kappa-opioid receptors
Kissler, J. L., Sirohi, S., Reis, D. J., Jansen, H. T., Quock, R. M., Smith, D. G., & Walker, B. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.014 · Cited by 145
“Conversely, DYNs are the endogenous ligands for the κ-opioid receptor (KOR) (11) and produce dysphoria in humans, aversive behavior in animals and have been implicated in alcohol abuse and dependence(12), as well as the reinforcing and rewarding properties of other drugs of abuse such as nicotine and cocaine(13;14).”
Opioid receptor reserve in normal and morphine-tolerant guinea pig ileum myenteric plexus
Chavkin, C., & Goldstein, A. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.22.7253 · Cited by 128
Self-citationMolecular and genetic substrates linking stress and addiction
Briand, L. A., & Blendy, J. A. (2010) · Brain Research · doi:10.1016/j.brainres.2009.11.002 · Cited by 125
“Dynorphin, an opiate peptide arising from the precursor prodynorphin, is the endogenous ligand for the kappa opioid receptor and is widely distributed throughout the brain (Chavkin et al., 1982).”
BackgroundForadori, C. D., Goodman, R. L., Adams, V. L., Valent, M., & Lehman, M. N. (2005) · Endocrinology · doi:10.1210/en.2004-1326 · Cited by 123
Schlosburg, J. E., Whitfield, T. W., Park, P. E., Crawford, E. F., George, O., Vendruscolo, L. F., & Koob, G. F. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1979-13.2013 · Cited by 119
κ-Opioid Receptors within the Nucleus Accumbens Shell Mediate Pair Bond Maintenance
Resendez, S. L., Kuhnmuench, M., Krzywosinski, T., & Aragona, B. J. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5779-11.2012 · Cited by 110
“Conversely, D1-expressing neurons contain dynorphin, the endogenous ligand for -opioid receptors that mediates aversion and negative affect (Chavkin et al., 1982; Mucha and Herz, 1985; Pfeiffer et al., 1986).”
BackgroundKarkhanis (2017) · doi:10.1016/bs.irn.2017.08.001 · Cited by 113
Anhedonia in depression symptomatology: appetite dysregulation and defective brain reward processing
Coccurello, R. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112041 · Cited by 106
Naltrexone and buprenorphine combination in the treatment of opioid dependence
Gerra, G., Fantoma, A., & Zaimovic, A. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060835 · Cited by 106
“…Trujillo and Akil, 1989; Smiley et al., 1990; Trujillo et al., 1990), suggesting that dynorphin, an endogenous k agonist (Chavkin et al., 1982; Corbett et al., 1982), might function as part of a homeostatic system to oppose the mood-enhancing and reinforcing effects of morphine (Spanagel et…”
BackgroundDopamine and opioid systems interact within the nucleus accumbens to maintain monogamous pair bonds
Resendez, S. L., Keyes, P. C., Day, J. J., Hambro, C., Austin, C. J., Maina, F. K., Eidson, L. N., Porter-Stransky, K. A., Nevárez, N., McLean, J. W., et al. (2016) · eLife · doi:10.7554/elife.15325 · Cited by 88
“Moreover, stimulation of D1-like receptors results in the production of dynorphin (Engber et al., 1992), the endogenous ligand for KORs (Chavkin et al., 1982) and activation of these receptors is also required for the expression of selective aggression (Resendez et al., 2012).”
Leitl, M. D., Onvani, S., Bowers, M. S., Cheng, K., Rice, K. C., Carlezon, W. A., Banks, M. L., & Negus, S. S. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.236 · Cited by 87
κ opioid receptors in the nucleus accumbens shell mediate escalation of methamphetamine intake
Whitfield, T. W., Schlosburg, J. E., Wee, S., Gould, A., George, O., Grant, Y., Zamora-Martinez, E. R., Edwards, S., Crawford, E., Vendruscolo, L. F., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.1978-13.2015 · Cited by 75
Bremazocine: A κ‐Opioid Agonist with Potent Analgesic and Other Pharmacologic Properties
Dortch‐Carnes, J., & Potter, D. E. (2005) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2005.tb00270.x · Cited by 47
Dynorphin and its role in alcohol use disorder
Karkhanis, A. N., & Al-Hasani, R. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146742 · Cited by 47
“, 1978), which ultimately resulted in confirmation that dynorphin A was an endogenous ligand for the ‘physically distinct, non-converting kappa opioid receptor’ (Chavkin, 2013; Chavkin et al., 1982).”
BackgroundSolecki, W., Ziolkowska, B., Krowka, T., Gieryk, A., Filip, M., & Przewlocki, R. (2009) · Brain Research · doi:10.1016/j.brainres.2008.12.002 · Cited by 39
Neuropeptide systems and new treatments for nicotine addiction
Bruijnzeel, A. W. (2017) · Psychopharmacology · doi:10.1007/s00213-016-4513-5 · Cited by 36
Nicotine increases alcohol intake in adolescent male rats
Lárraga, A., Belluzzi, J. D., & Leslie, F. M. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00025 · Cited by 33
Sandrini, M., Romualdi, P., Vitale, G., Morelli, G., Capobianco, A., Pini, L. A., & Candeletti, S. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00623-2 · Cited by 18
Wei, G., Sirohi, S., & Walker, B. M. (2022) · Addiction Biology · doi:10.1111/adb.13138 · Cited by 15
Gowrishankar, R., Hjort, M., Elerding, A. J., Shirley, S. E., Van Tilburg, J., Marcus, D. J., Senthilkumar, P., Abrera, K. A., Sumarli, D., Motovilov, K., et al. (2024) · doi:10.1101/2024.05.20.595035 · Cited by 3
Metadata
- Authors
- Chavkin, C., James, I. F., & Goldstein, A.
- Venue
- Science
- Published
- 1982-01-22
- Volume
- 215
- Issue
- 4531
- Pages
- 413-415
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2010531200
- Cited by
- 1,168
- References
- 29
- FWCI
- 27.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.